Key Points
- EVP Fady Ibraham Malik sold 3,500 shares of Cytokinetics on April 21 at an average price of $65.69 under a pre-arranged Rule 10b5-1 plan, trimming his stake to 153,902 shares (about $10.11M), a 2.22% ownership decrease.
- Those trades are part of a string of insider sales this quarter totaling 22,940 shares (Mar 9–Apr 21) for roughly $1.45M in proceeds, signaling continued insider selling activity.
- Analysts remain broadly positive with a consensus Moderate Buy and a $90.55 average price target, while CYTK trades in the mid-$60s with a market cap around $8.1B and a 52‑week range of $29.31–$70.98.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 3,500 shares of the business's stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $65.69, for a total value of $229,915.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares of the company's stock, valued at $10,109,822.38. The trade was a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Fady Ibraham Malik also recently made the following trade(s):
- On Tuesday, April 7th, Fady Ibraham Malik sold 4,500 shares of Cytokinetics stock. The shares were sold at an average price of $65.11, for a total value of $292,995.00.
- On Tuesday, March 17th, Fady Ibraham Malik sold 12,033 shares of Cytokinetics stock. The shares were sold at an average price of $62.15, for a total value of $747,850.95.
- On Monday, March 9th, Fady Ibraham Malik sold 2,907 shares of Cytokinetics stock. The shares were sold at an average price of $60.72, for a total value of $176,513.04.
Cytokinetics Stock Performance
Cytokinetics stock opened at $65.80 on Wednesday. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The company has a market capitalization of $8.10 billion, a P/E ratio of -10.08 and a beta of 0.47. The stock has a 50-day simple moving average of $64.27 and a 200-day simple moving average of $63.39.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same period in the prior year, the firm earned ($1.26) earnings per share. The business's revenue was up 4.9% on a year-over-year basis. As a group, analysts forecast that Cytokinetics, Incorporated will post -6.22 earnings per share for the current year.
Analyst Ratings Changes
CYTK has been the subject of several research reports. Mizuho boosted their target price on Cytokinetics from $84.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, March 18th. Morgan Stanley set a $90.00 price objective on Cytokinetics in a research note on Thursday, January 8th. Bank of America reaffirmed a "neutral" rating on shares of Cytokinetics in a research note on Wednesday, February 25th. Leerink Partners reaffirmed an "outperform" rating on shares of Cytokinetics in a research note on Tuesday, March 10th. Finally, Truist Financial upped their price objective on Cytokinetics from $84.00 to $92.00 and gave the company a "buy" rating in a research note on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $90.55.
Read Our Latest Report on Cytokinetics
Institutional Trading of Cytokinetics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can raised its stake in Cytokinetics by 1.2% during the 4th quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company's stock valued at $845,000 after acquiring an additional 160 shares during the last quarter. Kennedy Capital Management LLC raised its stake in shares of Cytokinetics by 1.2% during the 4th quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company's stock worth $838,000 after buying an additional 162 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Cytokinetics by 10.6% during the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 169 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 171 shares in the last quarter. Finally, Vident Advisory LLC raised its stake in shares of Cytokinetics by 1.4% during the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company's stock worth $1,046,000 after buying an additional 234 shares in the last quarter.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
